The Effects of Neprilysin on Glucagon-like Peptide-1 (NEP)
Diabetes, Heart Failure
About this trial
This is an interventional treatment trial for Diabetes focused on measuring GLP-1, Neprilysin, DPP-4
Eligibility Criteria
Inclusion Criteria:
- men
- body mass index between 20-25
Exclusion Criteria:
- acute diseases within the two weeks
- chronic diseases
- smoker
- alcoholism, drug addiction or recent weight loss
- blood donation within the last 3 months
Sites / Locations
- University of Copenhagen
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Placebo Comparator
Active Comparator
Active Comparator
Active Comparator
Placebo
Entrestro as single dose
Sitagliptin as single dose
Entrestro + sitagliptin as single dose
No treatment. Participants are subjected to a standardized meal
194 mg sacubitril / 206 mg valstartan (entresto) as one single dose followed by a standardized meal
200mg sitagliptin (100mg the night before and 100mg on the study day) as one single dose followed by a standardized meal
194 mg sacubitril / 206 mg valstartan (entresto) + 200mg sitagliptin (100mg the night before and 100mg on the study day) as one single dose followed by a standardized meal